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Background: To update and compare mortality from primary liver cancer (PLC) and intrahepatic cholangiocarcinoma
(ICC) in Europe in 1990–2010.
Materials and methods: We used data from the World Health Organization (WHO) to compute age-standardized
(world population) mortality rates, and used joinpoint analysis to identify substantial changes.
Results: Between 2002 and 2007, PLC rates in the European Union (EU) declined from 3.9 to 3.6/100 000 men.
Around 2007, the highest male rates were in France (6.2/100 000), Spain (4.9), and Italy (4.0), while the lowest ones
were in Sweden (1.1), the Netherlands (1.2), and the UK (1.8). In women, mortality was lower (0.8/100 000 in 2007 in
the EU), and showed more favourable trends, with a decline of over 2% per year over the last two decades as
compared with 0.4% in men, in the EU. In contrast, the EU mortality from ICC increased by around 9% in both sexes
from 1990 to 2008, reaching rates of 1.1/100 000 men and 0.75/100 000 women. The highest rates were in UK,
Germany, and France (1.2–1.5/100 000 men, 0.8–1.1/100 000 women).
Conclusions: PLC mortality has become more uniform across Europe over recent years, with an overall decline; in
contrast, ICC mortality has substantially increased in most Europe.
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introduction
Over the last few decades, rates and trends in mortality from
liver cancer have been considerably different across Europe [1,
2]. In the 1980s, mortality was about ﬁvefold higher in France
and Italy when compared with most of northern Europe, but
over the last two decades trends have been downwards in these
countries, while they have been upwards in the UK, Germany
and most other central European countries. Substantial
increases in liver cancer incidence over recent years took place
in Northern Europe and North America [3, 4].
Part of this variation may be due to a different proportion
and variable time trends of primary liver cancer (PLC, deﬁned
as including hepatocellular carcinoma (HCC) and other rarer
liver cancers, such as hepatoblastoma or angiosarcoma), versus
intrahepatic cholangiocarcinoma (ICC). These two neoplasms
have different sex ratios, with a much greater male
preponderance for HCC than for ICC [5]. The incidence of
ICC has also increased in the United States [6], though this
may be due—at least in part—to improved diagnosis and
pathological conﬁrmation.
The risk factors of HCC and ICC are—at least in part—
different: diabetes, heavy alcohol drinking and cirrhosis are
associated with both HCC and ICC, but the association with
hepatitis C virus (HCV) infection is much stronger for HCC
than for ICC [7–10], while history of gallstones is associated
with the risk of ICC, but not of HCC [11].
To provide updated information on trends in mortality from
PLC and ICC, and for comparative purpose, extrahepatic bile
ducts cancer (extrahepatic cholangiocarcinoma, ECC), we
considered data from major European countries up to 2010.
materials and methods
We extracted ofﬁcial death certiﬁcation data for PLC, ICC and ECC over
the period 1990–2010 from the World Health Organization (WHO)
database as available on electronic support [12]. We analysed data for 12
major selected European countries, i.e. those countries for which it was
possible to compute separate rates for PLC and ICC, and with more stable
data: Austria, the Czech Republic, Denmark, Finland, France, Germany,
Italy, the Netherlands, Portugal, Spain, Sweden, and the UK. To compute
rates for the European Union (EU) as a whole, we included data from the
same 12 countries plus Ireland, for a total of 379 out of 493 million
inhabitants (80%). We also analysed data for the United States, Japan, and
Australia for comparative purpose. For ICC, data were available since 1996
for Finland. For both PLC and ICC, data were available since 1994 up to
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2006 for Denmark, and up to 2006 for Australia, up to 2007 for the United
States, up to 2008 for France, Italy, and Spain, and up to 2009 for the
Czech Republic, Finland, Portugal, the UK, and Japan. In a few countries,
data were missing for one or more calendar years. No extrapolation was
made for missing years.
During the calendar period considered two different Revisions of the
International Classiﬁcation of Diseases (ICD) were used [13, 14]. Thus, we
considered ICD-9 code 155.0 and ICD-10 codes C22.0, C22.2–C22.4 and
C22.7 for PLC, and ICD-9 code 155.1 and ICD-10 code C22.1 for ICC.
Classiﬁcation of cancer deaths was re-coded, for all calendar periods and
countries, according to the 10th Revision of the ICD. For ECC, only data
with ICD-10 code C24.0 were used. For Sweden, only data since the 1997
were considered, because of substantial changes between the 9th and 10th
Revision of the ICD.
The estimates of the resident populations were obtained from the same
WHO database [12]. From the matrices of certiﬁed deaths and resident
populations, we computed age-speciﬁc rates for each 5-year age group
(from 0, 1–4, 5–9 to 80–84 and ≥85 years) and calendar year, separately
for men and women. We also computed age-standardized rates per 100 000
persons at all ages and truncated at age 45–64 years using the direct
method, on the basis of the world standard population [15].
To identify substantial changes in trends, we carried out joinpoint
regression analysis using the ‘Joinpoint’ software from the Surveillance
Research Program of the US National Cancer Institute [16]. This analysis
allows to identify the years where a substantial change in the linear slope of
the trend (on a log-scale) is detected over the study period [17]. The
estimated annual percentage change (APC) was then computed for each of
the identiﬁed trends by ﬁtting a regression line to the natural logarithm of
the rates using the calendar year as a regressor variable. Finally, to simplify
trend comparisons between sexes and countries, we also calculated the
average APC (AAPC) over the entire period 1990–2010 (when available),
based on an underlying joinpoint model. This was estimated as the
geometric weighted average of the APC, with the weights equal to the
length of each time interval segment [18].
results
Table 1 gives the overall age-standardized mortality rates per
100 000 men and women from PLC and ICC separately, in 12
selected European countries and in the EU, plus the United
States, Japan, and Australia, around 2002 (2000–2004) and
2007 (2005–2009), and the corresponding percentage changes
in rates. In the EU, the overall mortality rates from PLC
decreased from 3.9 to 3.6/100 000 men and from 0.93 to 0.77/
100 000 women between 2002 and 2007. Male mortality
decreased in Italy, the Czech Republic, Spain, and France, but
increased in all other European countries considered, except
Austria, where mortality remained stable. Within Europe, in
2007, the highest male mortality rates from PLC were in
France (6.2/100 000), Spain (4.9), Austria (4.3), and Italy (4.0),
while the lowest ones were in Sweden (1.1), the Netherlands
(1.2), the UK (1.8), and Denmark (1.9). Between 2002 and
2007, female mortality decreased particularly in Italy, Spain,
Denmark, and the Czech Republic, while increased in Sweden,
the Netherlands, and the UK. The mortality rates remained
almost stable in Austria, Finland, Germany, and Portugal. In
2007, the highest female mortality rates were around 1/100 000
in Spain and Italy, while the lowest ones were in Denmark
(0.32), Sweden, and the UK (0.41). In the United States, male
PLC mortality rates increased from 2.3 to 2.5/100 000 men; in
Japan, rates were appreciably higher, but decreased from 17.6
to 13.7/100 000 men; while in Australia they were almost stable
around 2.3/100 000 men. In women, rates were almost stable in
the United States (around 0.6) and in Australia (around 0.5),
and decreased from 5.1 to 4.1/100 000 women in Japan.
Male mortality rates from ICC increased from 0.79 to 1.1/
100 000 in the EU overall. Mortality rates rose in all European
countries considered, with the largest increases in Austria,
Denmark, France, Germany, Italy, and Spain. Within Europe,
in 2007, the highest male mortality rates from ICC were in
Austria, France, Spain, the UK, Finland, and Germany
(between 1.5 and 1.1/100 000 men), while the lowest ones were
in the Czech Republic, Sweden, the Netherlands, Denmark,
Italy, and Portugal (between 0.5 and 0.9/100 000 men). In
women, the EU rates increased from 0.55 in 2002 to 0.75/
100 000 women in 2007, and the patterns were similar to those
in men. From 2002 to 2007, the rates were stable in Japan
(around 1.1/100 000 men and around 0.6/100 000 women),
while the rates increased in the United States (from 0.73 to
0.82/100 000 men and from 0.56 to 0.64/100 000 women) and
Australia (from 0.94 to 1.2/100 000 men and from 0.76 to 0.91/
100 000 women).
Table 2 gives the corresponding mortality rates for men and
women aged 45–64 years. For PLC, the mortality rates
decreased from 7.4 in 2002 to 7.0/100 000 men in 2007, and
from 1.4 to 1.1/100 000 women in the EU. In 2007, the highest
male mortality rates were reported in France (12.7/100 000)
and Spain (10.2), while the lowest ones were in the
Netherlands and Sweden (2.5). In women, the mortality rates
varied from 0.7/100 000 women in the UK and in the
Netherlands to 1.5/100 000 women in France. Some increases
in PLC mortality were observed in the United States and
Australia, with rates, respectively, of 7.3 and 5.2/100 000 men
and 1.1–1.2/100 000 women in 2007, whereas substantial
declines were registered in Japan, though with exceedingly high
rates (25.1/100 000 men and 4.1/100 000 women in 2007). For
ICC, truncated 45–64 years mortality rates increased from 1.5
in 2002 to 2.0/100 000 in men in 2007, and from 1 to 1.3 in
women in the EU. In 2007, the highest male ICC mortality
rates were 3.0/100 000 men in Austria, and the lowest one was
1.0/100 000 men in Sweden. In women, the mortality rates
varied from 0.7/100 000 women in the Czech Republic and
Sweden to 2.0/100 000 women in Austria. Some increases in
mortality from ICC were observed in the United States and
Australia too, while some declines were registered in Japan.
Table 3 considers, for comparative purposes, trends in ECC
mortality. In the EU, the United States, and Australia, the
mortality rates were downwards, and three to ﬁve times lower
than those of ICC, i.e. between 0.06 and 0.27/100 000. In
Japan, ECC rates were much higher (around 3/100 000 men
and 1.5/100 000 women), and only moderately declined over
recent calendar periods.
The ﬁndings from the joinpoint regression analysis in men
and women at all ages, over the period 1990–2010, are given in
Figure 1 (and Supplementary Table S1, available at Annals of
Oncology online) for PLC, and in Figure 2 (and Supplementary
Table S2, available at Annals of Oncology online) for ICC. In all
European countries considered, mortality trends for PLC were
more frequently falling or levelling off in women than in men
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(Figure 1 and Supplementary Table S1, available at Annals of
Oncology online). The major change in PLC mortality was the
steady and substantial fall in Italy, with an AAPC of −4%
per year in men, and −5% in women. Other appreciable
declines were observed in the Czech Republic, France (after the
mid-1990s) and Spain (after 2000). In the EU, mortality from
PLC, after an increase in the early 1990s (APC = 5.1% in men
and 2.7% in women), started to decline since 1994
(APC =−1.9% in men, and −3.4% in women). In contrast,
recent trends were upwards in Germany, the UK, a few other
northern European countries, and Portugal, particularly in
men. PLC trends were upwards in US men (but not in
women), appreciably downwards in Japanese of both sexes
after 1996–1997 (by ∼4% per year), though Japanese rates for
PLC remain exceedingly high, while they were almost stable in
Australia in both sexes.
ICC mortality steadily increased throughout Europe, for
both sexes (Figure 2 and Supplementary Table S2, available at
Annals of Oncology online). The major rises were in Austria,
France, Germany, and Italy, with AAPCs for the entire period
around 13%–15% per year. EU mortality from ICC increased
by over 10% between 1990 and 2004–2005 in both sexes,
followed by smaller rises (APC = 2.2% in men, and 4.5% in
women) over most recent years. Trends were also upwards in
the United States, Japan, and Australia. In the United States,
the rates increased by ∼9% per year in men and women until
1993–1994, and by around 3.5% from 1993–1994 to 2007. In
Australia, a steady increase in ICC mortality was observed over
the entire period (APC ∼5% in men and 6% in women). In
Japan, trends steeply increased until the second mid of the
1990s (APC 30.4% per year in men and 26.7% in women), to
rise by only about 1% per year in both sexes, thereafter.
Table 1. Overall age-standardized (world population) mortality rates from primary liver cancer (PLC) and intrahepatic cholangiocarcinoma (ICC) per
100 000 men and women in selected European countries, the European Union (EU), the United States, Japan, and Australia, around 2002 (2000–2004) and
2007 (2005–2009), and the corresponding percentage changes in rates
Men Women
2002 2007 No. of deathsa % Change 2007/2002 2002 2007 No. of deathsa % Change 2007/2002
PLC
Austria 4.27 4.31 343 0.8 0.92 0.89 101 −3.5
Czech Republic 2.76 2.32 180 −15.9 0.99 0.76 78 −23.1
Denmark (2005–2006) 1.46 1.89 90 29.6 0.42 0.32 16 −25.1
Finland 2.68 2.97 163 10.7 0.91 0.89 74 −2.3
France (2005–2008) 6.73 6.21 3340 −7.8 0.95 0.85 735 −10.8
Germany 2.89 3.05 2727 5.4 0.75 0.76 954 1.9
Italy (2000–2003/2006–2008) 6.08 4.02 2462 −33.9 1.72 1.01 989 −41.5
The Netherlands 1.05 1.18 212 12.3 0.33 0.39 79 17.3
Portugal (2000, 2002–2003/2007–2009) 2.71 3.66 379 34.8 0.68 0.66 108 −2.1
Spain (2005–2008) 5.66 4.89 1927 −13.7 1.53 1.10 675 −28.1
Sweden 0.76 1.13 120 49.0 0.30 0.41 42 35.6
UK 1.40 1.83 1102 30.6 0.35 0.41 321 16.0
EU (2005–2008)b 3.88 3.56 12 696 −8.3 0.93 0.77 4114 −17.2
United States (2005–2007) 2.30 2.52 5428 9.6 0.58 0.59 1629 1.7
Japan 17.55 13.65 19 696 −22.3 5.05 4.06 9646 −19.6
Australia (2006) 2.34 2.26 349 −3.6 0.51 0.46 85 −10.7
ICC
Austria 1.02 1.50 118 46.8 0.71 1.07 128 50.6
Czech Republic 0.43 0.49 42 12.7 0.27 0.36 48 30.8
Denmark (2005–2006) 0.41 0.76 35 87.8 0.31 0.67 39 120.1
Finland 1.13 1.22 75 8.0 0.96 1.03 86 7.3
France (2005–2008) 1.04 1.35 835 30.0 0.59 0.84 781 40.7
Germany 0.64 1.06 1078 64.8 0.46 0.72 999 54.7
Italy (2000–2003/2006–2008) 0.48 0.79 495 65.6 0.31 0.50 499 62.8
Netherlands 0.58 0.63 119 9.4 0.43 0.46 112 7.8
Portugal (2000, 2002–2003/2007–2009) 0.79 0.94 99 19.3 0.39 0.50 75 29.4
Spain (2005–2008) 0.95 1.29 569 35.7 0.60 0.77 558 27.4
Sweden 0.42 0.49 55 15.9 0.38 0.39 60 5.0
UK 1.00 1.24 859 23.6 0.87 1.12 996 27.6
EU (2005–2008)b 0.79 1.07 4109 36.5 0.55 0.75 4244 36.2
United States (2005–2007) 0.73 0.82 1916 11.2 0.56 0.64 1939 13.8
Japan 1.08 1.09 1757 0.4 0.58 0.58 1304 −0.3
Australia (2006) 0.94 1.22 214 30.2 0.76 0.91 184 19.5
aNumber of deaths of the latest year available.
bIncluding data from 13 countries (Austria, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, Netherlands, Portugal, Spain, Sweden, and the UK).
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Table 2. Age-standardized (world population) mortality rates from primary liver cancer (PLC) and intrahepatic cholangiocarcinoma (ICC) per 100 000
men and women truncated at age 45–64 years, in selected European countries, the European Union (EU), the United States, Japan, and Australia, around
2002 (2000–2004) and 2007 (2005–2009), and the corresponding percentage changes in rates
Men Women
2002 2007 No. of deathsa % Change 2007/2002 2002 2007 No. of deathsa % Change 2007/2002
PLC
Austria 8.57 9.00 80 5.0 1.46 1.31 14 −9.7
Czech Republic 6.41 4.65 65 −27.5 1.88 1.40 21 −25.2
Denmark (2005–2006) 3.39 4.34 38 28.3 0.87 0.40 1 −54.7
Finland 4.05 4.44 40 9.7 1.13 1.27 10 12.2
France (2005–2008) 13.35 12.65 1046 −5.3 1.59 1.47 125 −7.7
Germany 5.53 5.85 667 5.8 1.28 1.30 150 0.9
Italy (2000–2003/2006–2008) 11.50 7.25 545 −37.0 2.30 1.15 85 −49.9
The Netherlands 2.20 2.50 72 14.0 0.63 0.71 20 12.2
Portugal (2000, 2002–2003/2007–2009) 6.41 8.69 126 35.4 1.16 1.00 15 −13.3
Spain (2005–2008) 10.92 10.19 556 −6.7 1.93 1.17 62 −39.5
Sweden 1.64 2.50 42 52.1 0.44 0.77 9 75.0
UK 2.77 3.77 328 35.8 0.62 0.69 64 10.1
EU (2005–2008)b 7.42 7.03 3551 −5.2 1.39 1.12 536 −19.0
United States (2005–2007) 6.15 7.26 2850 18.2 1.11 1.22 485 10.4
Japan 33.72 25.06 4289 −25.7 6.02 4.06 678 −32.5
Australia (2006) 4.85 5.20 127 7.3 0.95 1.12 28 18.6
ICC
Austria 1.88 3.02 33 60.8 1.41 2.01 29 42.3
Czech Republic 0.92 1.31 20 43.1 0.53 0.68 14 28.7
Denmark (2005–2006) 0.91 1.71 13 87.6 0.45 1.23 7 171.5
Finland 2.43 2.61 21 7.4 1.88 1.91 21 1.2
France (2005–2008) 2.27 2.56 231 13.1 1.00 1.60 156 59.8
Germany 1.30 2.01 255 53.9 0.82 1.28 164 55.8
Italy (2000–2003/2006–2008) 1.07 1.64 126 53.0 0.65 0.93 94 43.6
The Netherlands 1.03 1.10 30 6.9 0.79 0.76 22 −3.5
Portugal (2000, 2002–2003/2007–2009) 1.54 1.87 23 21.0 0.77 0.77 15 1.0
Spain (2005–2008) 1.55 2.23 121 43.4 0.83 1.15 72 38.5
Sweden 1.01 1.00 19 −1.1 0.85 0.70 13 −17.5
UK 1.73 1.94 165 12.0 1.57 1.94 167 23.6
EU (2005–2008)b 1.52 1.99 1031 30.9 0.97 1.33 768 37.6
United States (2005–2007) 1.43 1.61 584 12.9 1.13 1.28 527 13.4
Japan 1.99 1.95 385 −1.9 1.02 0.99 190 −3.2
Australia (2006) 1.56 1.85 47 18.6 1.43 1.46 36 1.9
aNumber of deaths of the latest year available.
bIncluding data from 13 countries (Austria, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden,
and the UK).
Table 3. Overall age-standardized (world population) mortality rates from extrahepatic bile ducts cancer per 100 000 men and women in the European
Union (EU), the United States, Japan, and Australia, around 2002 (2000–2004) and 2007 (2005–2009), and the corresponding percentage changes in rates
Men Women
2002 2007 No. of deathsa % Change 2007/2002 2002 2007 No. of deathsa % Change 2007/2002
EU (2005–2008)b 0.29 0.27 965 −6.2 0.25 0.21 1082 −17.0
United States (2005–2007) 0.16 0.13 302 −19.8 0.11 0.09 315 −17.0
Japan 3.15 2.99 5410 −4.9 1.71 1.53 4412 −10.3
Australia (2006) 0.20 0.06 12 −69.3 0.14 0.10 25 −28.0
aNumber of deaths for the latest year available.
bIncluding data from 13 countries (Austria, Czech Republic, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Portugal, Spain, Sweden,
and the UK).
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Figure 1. Joinpoint analysis for age-standardized (world population) death certiﬁcation rates from primary liver cancer (PLC) in 12 selected European
countries, the European Union (EU), the United States, Japan, and Australia, 1990–2010. Men, ; women .
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Figure 2. Joinpoint analysis for age-standardized (world population) death certiﬁcation rates from intrahepatic cholangiocarcinoma (ICC) in 12 major
selected European countries, the European Union (EU), the United States, Japan, and Australia, 1990–2010. Men, ; women .
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discussion
There are several important messages from this updated
analysis of trends of liver cancer mortality in Europe. PLC
(essentially HCC) has decreased over the last decade in
traditionally high mortality areas from southern European
countries, such as Italy and France, and recently Spain, but has
increased in former low mortality areas of central and northern
Europe, and in Portugal. Consequently, the mortality rates of
PLC have become more uniform across Europe over recent
years, being 3.6/100 000 men and 0.8/100 000 women in the
EU as a whole over the last period considered (2005–2008). In
most European countries, mortality trends from PLC in
women were more favourable than in men. In contrast,
mortality from ICC has increased in all EU countries
considered, and over recent years ICC accounted for over a
fourth of all liver cancer deaths in men and ∼50% in women.
Trends in PLC mortality in the United States and Australia
were similar to those observed in central and northern
European countries, showing upward trends particularly in
people aged 45–64 years, but more favourable trends in
women. The rates in Japan remain extremely high, even if
marked falls were observed since the mid-1990s. Upward
trends in ICC mortality were observed in the United States,
Japan, and Australia, too.
In the interpretation of trends in liver cancer mortality, great
caution is required, given the substantial problems of validity
of death certiﬁcation data, mainly due to the difﬁculty in
distinguishing primary and secondary liver neoplasms [2, 19].
For this reason, we have considered only a few selected
countries for which death certiﬁcation data appeared consistent
and valid. Still, even in Sweden, the majority of liver cancer
deaths are classiﬁed as liver unspeciﬁed [20].
Some of the observed trends may, therefore, be due to
changes in the classiﬁcation of the diseases. An additional
problem of classiﬁcation is posed by the particular case of hilar
tumours (also called ‘Klatskin’ tumours), since they are often
misclassiﬁed as ICC instead of ECC, due to their tendency to
quickly invade the liver [21, 22]. In parallel, in England and
Wales as well as in the United States, coding misclassiﬁcation
of hilar tumours from ECC to ICC before 2000 may have
contributed to earlier rises in ICC rates [23]. However, a
previous study on the impact of such misclassiﬁcation showed
that the incidence of ICC signiﬁcantly increased over time,
even after excluding deaths from hilar cancers [24]. Since the
change in classiﬁcation occurred in the early 2000s, this cannot
explain the recent rises in ICC and falls in ECC. Further, given
the much lower rates of ECC than ICC in Europe, any change
in classiﬁcation between ICC and ECC cancers is unlikely to
have had any strong impact on ICC rates. Some
misclassiﬁcation is also possible between HCC and ICC, but
this is difﬁcult to quantify.
In any case, the consistency of mortality trends at all ages
and in middle-age populations, and the differences observed
between sexes, weigh against the possibility that problems in
diagnosis and classiﬁcation explain the observed trends.
Trends in PLC, mainly HCC, across Europe can be largely
related to changes in hepatitis B virus (HBV) and HCV
prevalence in subsequent generations in various countries [2, 3,
25], since HBV and HCV are more strongly related to HCC
than to ICC. In southern Europe, the decreased prevalence of
HBV and HCV in younger generations, after the adoption of
HBV vaccination programs [26], and the reduction in alcohol
drinking over the last few decades likely explain the favourable
HCC trends in those countries. Conversely, whereas the
increasing prevalence of HCV (and HBV) infection and
alcohol consumption in central and northern European
countries accounts for the unfavourable trends in those areas
of the continent. The decline in the prevalence of tobacco
smoking—another recognized risk factor for HCC [27]—in
men from Western European countries may also have
favourably inﬂuenced HCC mortality trends.
Some of the risk factors shared by HCC and ICC, including
diabetes and cirrhosis [8, 9, 28–31], have shown unfavourable
patterns over recent years in central and eastern Europe [32,
33], this may at least in part explain the recent rises in HCC
and ICC, at least in these areas of Europe. Furthermore,
improvements in survival from cirrhosis have increased the
development and the identiﬁcation not only of PLC but also of
ICC [34].
It is more difﬁcult to explain the diverging trends in ICC
and ECC, since most risk factors are common to both sites [6,
8, 9, 35], though HCV and heavy alcohol drinking appear to be
more strongly related to ICC than ECC [9]. Likewise, gallstones
are related to both ICC and ECC, but they appear to have a
stronger association with ECC [11, 36]. Diagnosis of gallstones
and removal of gallbladder are considered the main reason for
the recent declines in gallbladder cancer mortality in Europe
[37] and other areas of the world [38, 39], and may also, at
least in part, explain the recent favourable trends in ECC.
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